Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Australia calls for release of 3.1 million vaccine doses, if EU not blocking exports

Published 04/06/2021, 07:44 PM
Updated 04/06/2021, 11:50 PM
© Reuters. FILE PHOTO: Vial labelled "AstraZeneca coronavirus disease (COVID-19) vaccine" placed on displayed EU flag is seen in this illustration picture

By Colin Packham

CANBERRA (Reuters) - Australia said on Wednesday it will ask the European Union to release more than 3 million doses of AstraZeneca (NASDAQ:AZN) PLC's COVID-19 vaccine, testing Brussels claim it is not blocking shipments, as the country struggles to vaccinate its population.

The European Union (EU) on Tuesday denied blocking vaccine shipments to Australia, which has fallen dramatically behind in its scheduled vaccination programme.

The EU said it was not responsible for AstraZeneca's failure to uphold commitments to other countries. AstraZeneca did not immediately reply to a request for comment on Wednesday.

Prime Minister Scott Morrison said Australia was asked by the EU to withdraw export permit applications and letters requesting supplies have gone unanswered.

Morrison said if the EU was now indicating its willingness to release shipments, he would again ask for the 3.1 million doses to be released. The 3.1 million doses were scheduled to arrive in Australia by the end of March.

"We obviously want those millions of doses," Morrison told reporters in the capital Canberra.

"Given statements made overnight, that apparently there is no obstruction to that and then I would hope that could be readily addressed."

Morrison on Wednesday insisted he was not criticising the EU, but senior members of his government continued to blame the EU for blocking vaccines.

"They’re not giving approval is effectively the same as blocking," Australia's Treasurer Josh Frydenberg told Australian Broadcasting Corporation radio.

Australia says the delay in receiving the 3.1 million additional doses is why it has fallen behind in vaccinations.Only about 670,000 people have been vaccinated against an initial government target of 4 million by March-end.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Australia has recorded a small number of COVID cases compared to most nations and has now eradicated the virus from its community, but its slow vaccine roll out is pressuring Morrison who is struggling in the polls a year out from the next election after a series of damaging allegations about the mistreatment of female lawmakers and staff in his Liberal party.

THE STRUGGLE TO VACCINATE

The dispute between Australia and the EU emphasises the challenge facing European nations which are struggling to vaccinate their own populations and the impact of new EU vaccine export controls on countries that had pre-ordered doses.

Australia received an initial shipment of 300,000 doses of the AstraZeneca vaccine in late February, which it said was the last it received. Last month the EU, at Italy's request, blocked a shipment of 250,000 doses of the AstraZeneca PLC vaccine to Australia, citing vaccine shortages in Europe.

The AstraZeneca vaccine from Europe was to underpin the early stages of Australia's vaccine drive, supplementing 50 million shots of the vaccine that will be produced locally by CSL (OTC:CSLLY) Ltd. It has also imported doses of Pfizer Inc (NYSE:PFE)'s vaccine for frontline COVID workers.

Australia has recorded just over 29,000 cases and 909 deaths since the pandemic began.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.